- OUR CASES
-
Join Us
- Current Issues
-
About
NHMRC recommends kids use puberty blockers despite weak evidence
Australia’s leading medical research body has found that evidence for some of the most significant claimed benefits of puberty blockers for children is highly uncertain.
Yet despite these findings, the National Health and Medical Research Council (NHMRC) has recommended that the drugs remain an option for children experiencing gender confusion.
The NHMRC’s interim advice, released on November 16, found that evidence about the effect of puberty blockers on quality of life and wellbeing was “very uncertain”.
The evidence that puberty blockers reduce suicidal behaviours was also rated as “very low” certainty.
While the review identified possible improvements in psychological and social functioning, the evidence supporting these benefits was also of low certainty.
These findings should give doctors, parents, and policymakers serious pause.
Instead, the NHMRC’s Gender Guidelines Development Committee has made a conditional recommendation allowing puberty blockers to be considered for children who have commenced puberty, including those experiencing no gender-related distress.
The committee argued that making these children wait until they were distressed before accessing treatment would be “unethical”.
But where is the medical justification for intervening in a child's healthy development when the evidence of wider benefits remains so uncertain?
As The Australian has reported, critics have questioned why the NHMRC's assessment has resulted in a recommendation that largely preserves existing clinical practice.
The findings also raise questions about Australia's direction compared with the United Kingdom, where the landmark Cass Review prompted the NHS to end routine prescribing of puberty blockers for children in 2024.
There are some important safeguards in the NHMRC's advice.
It explicitly calls for comprehensive health assessments, appropriate multidisciplinary input and informed consent. Doctors must explain the potential benefits, risks and side effects, as well as reasonable alternatives, including no treatment.
These requirements must be taken seriously. Medical treatment should never follow an automatic pathway simply because a child expresses a desire for it.
The findings also reinforce the importance of the concerns raised by HRLA client Dr Jillian Spencer.
Dr Spencer was suspended from Queensland Children's Hospital in 2023 after raising concerns about puberty blockers and the treatment of children experiencing gender distress.
Following more than three years of proceedings, Children’s Health Queensland acknowledged that her concerns were legitimate matters of professional and public debate.
The NHMRC's latest findings demonstrate why doctors like Dr Spencer must be free to question prevailing medical practices without fear of punishment.
The NHMRC must reconsider whether its conditional recommendation is justified by the available evidence.
HRLA will continue defending medical professionals who raise legitimate concerns about the treatment of vulnerable children.
When the truth is at stake, people must be free to speak openly without fear of censure or professional discipline.
And when children's health and futures are at stake, evidence and patient safety must come before ideology.
Do you like this page?